MDG1015 is a first-in-class, 3rd generation T cell receptor engineered T cell (TCR-T) therapy targeting NY-ESO-1/ LAGE-1a, a well-recognized and validated cancer testis antigen, which is expressed in ...

(Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, announces today that ...

Its End-to-End Platform is built on multiple proprietary and exclusive technologies that enable the Company to generate optimal T cell receptors against both cancer testis antigens and neoantigens, ...

Medigene AG (Medigene or the "Company", FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies ...

Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today ...

There is no universally accepted mechanism to explain testis descent and the reason for the inhibition of testicular descent. An overlooked explanation to date seems to provide the most satisfactory ...

Families of men diagnosed with infertility could be at a higher risk of certain cancers, including those of colon and testis, according to a new study. While it is known that men experiencing ...

Background: Adenocarcinoma of the rete testis (AORT) is an extremely rare and aggressive tumor with a poor prognosis. Its etiology and pathological characteristics have not been extensively studied, ...

As with any procedure, there are risks to a spermatic cord denervation, such as: no pain relief, hydrocele formation (fluid accumulation in the testicles), loss or compromise of the testis, and ...